181 related articles for article (PubMed ID: 34606736)
21. Challenges in the Treatment of Newly Diagnosed and Recurrent Primary Central Nervous System Lymphoma.
Holdhoff M; Mrugala MM; Grommes C; Kaley TJ; Swinnen LJ; Perez-Heydrich C; Nayak L
J Natl Compr Canc Netw; 2020 Nov; 18(11):1571-1578. PubMed ID: 33152700
[TBL] [Abstract][Full Text] [Related]
22. Results of intensive chemotherapy followed by hematopoietic stem-cell rescue in 22 patients with refractory or recurrent primary CNS lymphoma or intraocular lymphoma.
Soussain C; Suzan F; Hoang-Xuan K; Cassoux N; Levy V; Azar N; Belanger C; Achour E; Ribrag V; Gerber S; Delattre JY; Leblond V
J Clin Oncol; 2001 Feb; 19(3):742-9. PubMed ID: 11157026
[TBL] [Abstract][Full Text] [Related]
23. New hopes in relapsed refractory primary central nervous system lymphoma.
Calimeri T; Steidl C; Fiore P; Ferreri AJM
Curr Opin Oncol; 2023 Sep; 35(5):364-372. PubMed ID: 37551946
[TBL] [Abstract][Full Text] [Related]
24. [Results of intensive chemotherapy followed by hematopoietic stem-cell rescue in 22 patients with refractory or recurrent primary CNS lymphoma or intraocular lymphoma].
Soussain C; Hoang-Xuan K; Levy V
Bull Cancer; 2004 Feb; 91(2):189-92. PubMed ID: 15047459
[TBL] [Abstract][Full Text] [Related]
25. [Primary central nervous system lymphoma: advances in treatment strategies].
Kondo E
Rinsho Ketsueki; 2020; 61(5):510-519. PubMed ID: 32507817
[TBL] [Abstract][Full Text] [Related]
26. [Clinical characteristics and prognosis of 49 newly diagnosed primary central nervous system diffuse large B-cell lymphoma].
Song J; Liu H; Shen HL; Yue LZ; Yang XJ; Song WJ; Sun CY; Yu SZ; Ding K; Wang YH; Li LJ; Yu H; Shao YY; Wang CM; Yue SY; Fu R
Zhonghua Xue Ye Xue Za Zhi; 2021 Nov; 42(11):917-922. PubMed ID: 35045653
[No Abstract] [Full Text] [Related]
27. Testicular Relapse of Primary Diffuse Large B-cell Lymphoma of the Central Nervous System - a Rare Occurrence.
Ollila TA; Kishkovich TP; Olszewski AJ; Patel NR; Jackson C; Roussel B; Niroula R; Treaba DO
R I Med J (2013); 2023 Mar; 106(2):8-12. PubMed ID: 36848533
[TBL] [Abstract][Full Text] [Related]
28. High-dose chemotherapy with thiotepa, busulfan, and cyclophosphamide and autologous stem cell transplantation for patients with primary central nervous system lymphoma in first complete remission.
DeFilipp Z; Li S; El-Jawahri A; Armand P; Nayak L; Wang N; Batchelor TT; Chen YB
Cancer; 2017 Aug; 123(16):3073-3079. PubMed ID: 28369839
[TBL] [Abstract][Full Text] [Related]
29. Aberrant methylation in the promoter region of the reduced folate carrier gene is a potential mechanism of resistance to methotrexate in primary central nervous system lymphomas.
Ferreri AJ; Dell'Oro S; Capello D; Ponzoni M; Iuzzolino P; Rossi D; Pasini F; Ambrosetti A; Orvieto E; Ferrarese F; Arrigoni G; Foppoli M; Reni M; Gaidano G
Br J Haematol; 2004 Sep; 126(5):657-64. PubMed ID: 15327516
[TBL] [Abstract][Full Text] [Related]
30. Primary central nervous system lymphoma (PCNSL) in older patients.
Bertucci A; Harlay V; Chinot O; Tabouret E
Curr Opin Oncol; 2023 Sep; 35(5):373-381. PubMed ID: 37498077
[TBL] [Abstract][Full Text] [Related]
31. Array-based profiling of the lymphoma cell DNA methylome does not unequivocally distinguish primary lymphomas of the central nervous system from non-CNS diffuse large B-cell lymphomas.
Vogt J; Wagener R; Montesinos-Rongen M; Ammerpohl O; Paulus W; Deckert M; Siebert R
Genes Chromosomes Cancer; 2019 Jan; 58(1):66-69. PubMed ID: 30284345
[TBL] [Abstract][Full Text] [Related]
32. Primary central nervous system lymphoma: advances in its pathogenesis, molecular markers and targeted therapies.
Hernández-Verdin I; Morales-Martínez A; Hoang-Xuan K; Alentorn A
Curr Opin Neurol; 2022 Dec; 35(6):779-786. PubMed ID: 36367044
[TBL] [Abstract][Full Text] [Related]
33. Application of new targeted drugs in relapsed/refractory primary central nervous system lymphoma.
Zhou Y; Xu X
Hematology; 2022 Dec; 27(1):105-112. PubMed ID: 35068379
[TBL] [Abstract][Full Text] [Related]
34. Therapeutic management of refractory or relapsed primary central nervous system lymphomas.
Reni M; Ferreri AJ
Ann Hematol; 2001; 80 Suppl 3():B113-7. PubMed ID: 11757691
[TBL] [Abstract][Full Text] [Related]
35. High-dose thiotepa, busulfan, cyclophosphamide and ASCT without whole-brain radiotherapy for poor prognosis primary CNS lymphoma.
Cheng T; Forsyth P; Chaudhry A; Morris D; Glück S; Russell JA; Stewart DA
Bone Marrow Transplant; 2003 Apr; 31(8):679-85. PubMed ID: 12692608
[TBL] [Abstract][Full Text] [Related]
36. High-dose chemotherapy and autologous stem cell transplantation for primary central nervous system lymphoma: a multi-centre retrospective analysis from the United Kingdom.
Kassam S; Chernucha E; O'Neill A; Hemmaway C; Cummins T; Montoto S; Lennard A; Adams G; Linton K; McKay P; Davies D; Rowntree C; Easdale S; Eyre TA; Marcus R; Cwynarski K; Fox CP
Bone Marrow Transplant; 2017 Sep; 52(9):1268-1272. PubMed ID: 28581466
[TBL] [Abstract][Full Text] [Related]
37. A focus on pharmacotherapy for primary central nervous system lymphoma.
Korfel A
Expert Rev Hematol; 2015 Oct; 8(5):559-62. PubMed ID: 26159859
[TBL] [Abstract][Full Text] [Related]
38. Upfront thiotepa, busulfan, cyclophosphamide, and autologous stem cell transplantation for primary CNS lymphoma: a single centre experience.
Alimohamed N; Daly A; Owen C; Duggan P; Stewart DA
Leuk Lymphoma; 2012 May; 53(5):862-7. PubMed ID: 22023529
[TBL] [Abstract][Full Text] [Related]
39. The role of upfront autologous stem cell transplantation in high-risk younger patients with primary central nervous system lymphoma.
Cho H; Chang JH; Kim YR; Kim SJ; Chung H; Park H; Lee JY; Jang JE; Kim Y; Kim SH; Yang WI; Suh CO; Cheong JW; Min YH; Kim JS
Br J Haematol; 2016 Aug; 174(3):444-53. PubMed ID: 27018207
[TBL] [Abstract][Full Text] [Related]
40. Treatment with methotrexate, rituximab, and cytosine arabinoside followed by autologous stem cell transplantation in primary central nervous system lymphoma: A single-center experience.
Atilla PA; Atilla E; Bozdag SC; Yuksel MK; Toprak SK; Topcuoglu P; Demirer T; Ilhan O; Arslan O; Gurman G; Ozcan M
Hematol Oncol Stem Cell Ther; 2018 Mar; 11(1):13-17. PubMed ID: 28633037
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
